TABLE 7.

Summary of reviewed studies dealing with MB/BacT systema

DrugAuthors (reference)YrCC (μg/ml)No. of:Sens.Spec.PPVNPVDOR
Tested strainsTPFNFPTN
SMBrunello and Fontana (9)20001.01201150051.001.001.001.007.84
Tortoli et al. (38)b20001.01139531140.970.930.990.826.09
Ängeby et al. (3)b20030.9503240141.000.780.891.005.34
Bemer et al. (7)20040.4516614020240.991.001.000.927.92
INHBrunello and Fontana (9)20001.012010302151.000.880.981.007.16
Tortoli et al. (38)20001.01138601261.000.960.991.008.02
Ängeby et al. (3)20030.09502301261.000.960.961.006.72
Bemer et al. (7)20040.0916613100351.001.001.001.009.83
RMPBrunello and Fontana (9)20001.01201160041.001.001.001.007.65
Tortoli et al. (38)20001.01139510170.991.001.000.947.71
Ängeby et al. (3)20030.9502502231.000.920.931.006.17
Bemer et al. (7)20040.916614800181.001.001.001.009.30
EMBBrunello and Fontana (9)20002.01201095060.961.001.000.555.56
Tortoli et al. (38)20002.01139432140.970.880.980.825.39
Ängeby et al. (3)20033.550440061.001.001.001.007.05
Bemer et al. (7)20043.516615301121.000.920.991.007.85
PZATortoli et al. (38)200050106971080.991.001.000.897.01
Bemer et al. (7)20042001661570091.001.001.001.008.70
  • a Data are reported by individual drug. TP, true positive; FN, false negative; FP, false positive; TN, true negative; Sens., sensitivity; Spec., specificity; PPV, positive predictive value; NPV, negative predictive value. DORs are expressed as logarithms.

  • b Resolution of discrepancies not performed.